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Advances in Understanding and Management of
Myeloproliferative Neoplasms
Alessandro M. Vannucchi, MD1; Paola Guglielmelli, MD2; Ayalew Tefferi, MD3
Abstract
According to the 2008 World Health Organization classification system for hematologic malignancies, the
myeloproliferative neoplasms (MPN) include chronic myelogenous leukemia, polycythemia vera, essential
thrombocythemia, primary myelofibrosis, mastocytosis, chronic eosinophilic leukemia-not otherwise specified,
chronic neutrophilic leukemia, and “MPN, unclassifiable.” All of these clinicopathologic entities are characterized by
stem cell-derived clonal myeloproliferation, and their phenotypic diversity is ascribed to the occurrence of distinct
oncogenic events. In the last 4 years, new JAK2 and MPL mutations have been added to previously described ABL
and KIT mutations as molecular markers of disease in MPN. These discoveries have markedly simplified the
approach to clinical diagnosis and have also provided molecular targets for the development of small-molecule
drugs. In the current article, the authors provide a clinically oriented overview of MPNs in terms of their molecular
pathogenesis, classification, diagnosis, and management. CA Cancer J Clin 2009;59:171-191. ©2009 American
Cancer Society, Inc.
To earn free CME credit or nursing contact hours for successfully completing the online quiz based on this article, go
to http://CME.AmCancerSoc.org.
Introduction
In 1951, William Dameshek1 introduced the term ”myeloproliferative disorders (MPD)” to encompass polycy-
themia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF),2 chronic myelogenous leuke-
mia (CML), and Di Guglielmo’s syndrome (erythroleukemia). His proposal was based on similarities in the
clinical phenotype of these disorders and on the hypothesis that a generalized proliferation of bone marrow cells,
due to some unknown stimuli, was the underlying cause. The association of the Philadelphia (Ph1)-chromosome
with CML in 1960,3 and the subsequent recognition of erythroleukemia as a variant of acute myeloid leukemia
(AML), distinguished the other three disorders as “classic” Ph1-negative MPD.4
The first systematic attempt to classify MPD and MPD-like clinicopathologic entities was undertaken by the
World Health Organization (WHO) committee for the classification of hematologic malignancies.5 According
to the 2001 WHO classification system, CML, PV, ET, and PMF were included under the category of “chronic
myeloproliferative diseases” (CMPD). The CMPD category also included other “nonclassic” MPD-like disorders
such as chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia/hypereosinophilic syndrome (CEL/
HES), and “unclassified CMPD.” The identification of BCR-ABL as a CML-specific genetic event, in the
context of CMPD, has facilitated accurate molecular diagnosis and effective targeted therapy. The lack of
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knowledge, until recently, on
specific genetic defects in the
other BCR-ABL-negative classic
CMPDs necessitated that diag-
nosis rest on a combination of
bone marrow histology and a
few clinical and laboratory find-
ings to distinguish clonal from
reactive myeloproliferation and
one CMPD from another.6
The last 4 years have wit-
nessed fundamental advances in
understanding the molecular
pathogenesis of classic BCR-
ABL-negative CMPD, capped
by the discovery of specific mo-
lecular abnormalities associated
with PV, ET, and PMF.7 As a
result, WHO diagnostic criteria
have been revised,8 and the term
“CMPD” has been changed to
“myeloproliferative neoplasms
(MPN).”8 It is hoped that newly
discovered mutations will also fa-
cilitate development of targeted therapy. At the same
time, large clinical studies continue to provide practi-
cally useful clinical information.
The current review has two main objectives. The first
is to provide a general overview ofMPN including their
molecular pathogenesis and updated WHO classifica-
tion. The second objective is to describe in more detail
the criteria for diagnosis, risk stratification, and man-
agement of patients with the classic BCR-ABL-nega-
tive MPN including PV, ET, and PMF.
Molecular Basis of Myeloproliferative
Neoplasms
Apart from the BCR/ABL rearrangement in CML,
originated by a reciprocal translocation between
chromosomes 9 and 22, t(9;22)(q34; q11),9 or the
chimeric FIP1L1-PDGFRA mRNA in some forms
of eosinophilia,10 and kit mutations in cases with
systemic mastocytosis,11 information concerning mo-
lecular abnormalities of MPN has been scanty until
2005, when a Janus kinase 2 mutation (JAK2V617F)
was discovered in the majority of patients with PV
and in 50% or fewer of those with ET or PMF.12-15
In the following 2 years, additional mutations in
JAK216 and MPL17,18 were reported (Table 1). These
different mutant alleles all result in a gain of function
due to the constitutive activation of tyrosine kinase-
dependent cellular signaling pathways, particularly of
the JAK-STAT pathway.19,20 Overall, this would
suggest that mutated kinases represent a common
pathogenetic mechanism in these disorders and that,
as exemplified by the efficacy of the tyrosine kinase
inhibitor imatinib in CML, they could represent
valid targets for therapy.21,22
Members of the Janus kinase family (JAK1, JAK2,
JAK3, and tyrosine kinase 2-Tyk2) are named after
the Roman god with two faces, meaning ending and
beginning, because they contain two symmetrical ki-
nase-like domains: the C-terminal JAK homology 1
(JH1) domain possesses tyrosine kinase function,
whereas the immediately adjacent JH2 domain is
enzymatically inactive, but it is credited with nega-
tively regulating the activity of JH1.23,24 Ordinarily,
JAKs are associated in an inactive state to the cyto-
plasmic tail of type 1 or type 2 cytokine receptors (eg,
erythropoietin receptor, EpoR; thrombopoietin re-
ceptor, MPL; granulocyte colony-stimulating factor
receptor, G-CSFR; and interferon-gamma receptor,
TABLE 1. Recurrent Molecular Abnormalities Associated with Myeloproliferative
Neoplasms
GENETIC ABNORMALITY DISEASE FREQUENCY
BCR-ABL Chronic myelogenous leukemia 99%
JAK2V617F Polycythemia vera 95%
Essential thrombocythemia 60%
Primary myelofibrosis 60%
MPN, unclassifiable 20%
Refractory anemia with sideroblasts and
thrombocytosis (RARS-T)
50%
JAK2 exon 12 Polycythemia vera 2%
MPLW515L/K* Primary myelofibrosis 8%
Essential thrombocythemia 8%†
Involving PDGFRA Myeloid neoplasms with eosinophilia Unknown
Mast cell disease Unknown
Involving PDGFRB Myeloid neoplasms with eosinophilia Unknown
Involving FGRF1 Myeloid neoplasms with eosinophilia Unknown
Involving KIT (D816V as the most frequent) Mast cell disease Unknown
MPN indicates myeloproliferative neoplasm.
*Other infrequent mutations, such as W515A or S505N, have been reported.
†Calculated on JAK2V617F-negative patients.
Myeloproliferative Neoplasms
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to name a few). After the engagement of the receptor
by corresponding ligand, JAK undergoes a confor-
mational change and becomes activated via phospho-
rylation of key tyrosine residues. In turn, phospho-
rylated JAKs mediate phosphorylation of tyrosine
residues of the cytoplasmic domain of the receptors
and create a docking site for the recruitment of
several proteins, ultimately leading to activation of
the signal transducer and activator of transcription
(STAT), the mitogen-activated protein (MAP) ki-
nase, and the phosphatidylinositol 3-kinase-AKT
(PI3K-AKT) pathways25 (Fig. 1A). Activated
STATs dimerize and translocate to the nucleus
where they regulate transcription after binding to
specific consensus sequences in the promoter regions
of several target genes (Fig. 1A). The entire process
is tightly controlled at multiple levels by protein
tyrosine phosphatases, suppressors of cytokine sig-
naling (SOCS), and protein inhibitors of activated
STAT.26-29 JAK2, and possibly other JAKs, is also
involved in the expression of cognate receptors
EPOR and MPL at the cell surface by acting as a
chaperon and protein stabilizer.30,31
The JAK2V617F mutation is a somatically ac-
quired G to T nucleotide shift at position 1849 in
exon 14 that results in a valine to phenylalanine
substitution at codon 617; the mutation is located in
the JH2 pseudo-kinase domain and is believed to
result in the loss of auto-inhibitory control of JAK2
(Fig. 1B). As a consequence, mutated JAK2 is in a
constitutively phosphorylated state, independent
from the binding of ligand to its receptor; in fact,
when the mutation is introduced into cytokine-de-
pendent cell lines it results in a cytokine-independent
growth of the cells and their hypersensitivity to cy-
tokines,13,14 mimicking the in vitro growth pattern of
hematopoietic progenitors from MPN patients. In
particular, the gain of function of mutated JAK2
provides a mechanistic explanation for the phenom-
enon of endogenous erythroid colony formation
(EEC),33,34 ie, the capacity of erythroid progenitors
to spontaneously produce hemoglobinized colonies
in vitro in the absence of added erythropoietin, a
hallmark of PV and other classic MPNs. Further-
more, transplantation of JAK2V617F mutated cells
induced a PV-like phenotype in recipient mice,13,35-38
accompanied by leukocytosis of a different extent and
eventually followed by changes suggestive of myelo-
fibrotic transformation.35-38 More recently, by ma-
nipulating expression levels of the V617F allele, mice
with an ET-like phenotype were also generated in
the presence of low levels of mutated JAK2.39 Over-
FIGURE 1. (A) In normal hematopoietic cells, signaling is initiated when cyto-
kines bind to and activate their cell surface type-1 receptors, which havemolecules
of JAK2 associated to the cytoplasmic domains. After ligand engagement (the
pathway activated by EPO bound to the EPOR is herein schematized) the receptor-
associated JAKsbecomeactivated throughauto-phosphorylation andon turnphos-
phorylate tyrosine residues in the receptor cytoplasmic tail. The receptor phospho-
tyrosines serve as docking sites for the recruitment of inactive cytoplasmic STAT
monomers through interaction with their SH2 domain. JAK-mediated phosphoryla-
tion of tyrosine residues on the receptor-bound STAT monomer induces STATs
dimerization. The activated dimers translocate to the nucleus, where they bind to
specific DNA-responsive elements in the promoters of target genes and thereby
induce unique gene expression program(s). Activation of JAK2 pathway also results
in the recruitment and activation of MAPk signaling proteins and AKT/mTOR/
FOXOpathway that transmit signals for survival, proliferation, and differentiation of
erythroblastic progenitors; JAK2-independent activation of these pathways might
also occur. Negative feedback mechanisms are normally mediated, among other
regulators, by SOCS proteins. These complex signals are autonomously activated,
in the absence of binding of the cytokine to its receptor, when JAK2 is mutated
(JAK2V617For activatingmutations in exon12) or the receptor itself ismutated (as
is the case of W515L/K mutation of MPL receptor). (B) Schematic representation
of the most common genetic abnormalities associated with MPN. For details,
please refer to text.
STAT indicates signal transducer and activator of transcription; AKT, protein kinase
B, PKB; FOXO, forkhead transcription factors; PI3K, phosphatidylinositol-3-kinase;
MAPK, mitogen-activated protein kinase; mTOR, mammalian target of rapamycin;
SOCS, suppressor of cytokine signaling; JAK2, Janus kinase 2 gene;MPL, thrombo-
poietin receptor gene; FIP1L1-PDGFRA, fusion gene of Fip1-like 1 with platelet-
derived growth factor receptor alpha; kit: stem cell factor (SCF) receptor gene;
FERM: 4-point-1, Erzin, Radixin, Moesin JAK2 amino-terminal domain; JH1, JAK
homology 1 (active tyrosine kinase) domain; JH2, JAK homology 2 (catalytically
inactive pseudokinase) domain; SH2, SRC homology 2 domain; HRD1, HRD2, He-
matopoietin/cytokine receptor domain1 (negative regulatory domain) or domain2
(ligand binding region); SP, signal peptide; TM, trans-membrane domain; JM, jux-
tamembrane domain; Ig, Immunoglobuline-like repeat; K1, Kinase domain 1; KI, 76
amino acids kinase insert domain; K2, kinase domain 2.
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all, these models indicated that the JAK2V617F mu-
tation is sufficient to induce a MPN-like phenotype
in mice and suggested that the level of mutated allele
may influence disease phenotype.40
Mutational frequency of JAK2V617F is estimated
to be more than 95% in PV, 60% in ET or PMF,
40% to 50% in refractory anemia with ringed sidero-
blasts and thrombocytosis (RARS-T),41 whereas it is
very rare in AML or MDS.42-45 In most patients with
PV or PMF, as opposed to a minority of those with
ET, the mutation is harbored in a homozygous state,
which is accomplished by mitotic recombination.12-15
In general, the highest V617F allele burden, that is the
level of mutated allele relative to normal allele in a cell
suspension such as granulocytes, is found in patients
with PV followed by PMF and ET46,47; however, such
variability in the allele burden does not represent a
sufficient criterion for distinguishing among different
clinical entities, nor does it satisfactorily help to explain
the apparent paradox of “one mutant allele-different
clinical phenotypes.” In fact, how a single V617F mu-
tation can be the basis of different clinical disorders, as
in the classic MPN, is still unclear. Interestingly, single
nucleotide polymorphisms (SNPs) in JAK2 have been
associated preferentially with the diagnosis of PV,48
supporting the contribution of inherited host genetic
characteristics to MPN phenotypic variability. Regard-
less, there is evidence to suggest that JAK2V617F may
not be the initial clonogenic event in MPN and that a
“pre-JAK2” mutated cell may exist.49,50 In support of
this is also a finding that leukemic blasts in patients who
evolve to AML from a pre-existing JAK2V617F-posi-
tive MPN are often negative for the JAK2V617F mu-
tation.51,52 Conversely, JAK2V617F, or other JAK2mu-
tations, are likely a necessary component of the PV
phenotype because they are detected in virtually all
patients with the disease53 and are sufficient to repro-
duce the phenotype in mice. In summary, JAK2V617F
mutation is integral to the classic MPN, but its exact
hierarchical position in pathogenesis and its role in
phenotypic variability remain to be clarified. After all,
one could conclude that PV, ET, and PMF are separate
diseases or different presentations or different phases of
a unique disease. It has been suggested that the pheno-
type of patients with JAK2V617F-positive ET resem-
bles “forme fruste” of PV.54
In patients with a clinical picture suggestive of PV
and who were found to be negative for the
JAK2V617F mutation, several genetic abnormalities
(ie, mutations, deletions, insertions) have been de-
tected in a short region of JAK2 exon 12 (Fig.
1B).16,55 These mutations, which probably account
for less than 2% of patients with PV,55 affect auton-
omous cell proliferation and differentiation in a fash-
ion similar to that of the V617F allele.16
Another recurrent molecular abnormality of MPN
is represented by somatic mutations at codon 515 of
MPL,17,18 which, as is the case with JAK2V617F,
involve early myeloid and lymphoid progenitors.56-58
MPL (named after myeloproliferative leukemia virus
oncogene homolog) is the receptor for the cytokine
thrombopoietin (Tpo) and is highly expressed in
early hematopoietic progenitors and in cells of the
megakaryocytic lineage.59 The two most common
MPL mutations, which are located in the cytoplasmic
juxtamembrane portion, are represented by W515L
(a tryptophan to leucine substitution) and W515K (a
tryptophan to lysine substitution; Fig. 1B). They
have been detected in 5% to 11% of patients with
PMF17,18,60 and in up to 9% of JAK2V617F-negative
cases of ET.61,62 Other unusual MPL mutations (eg
MPLW515S, W5151A, and MPLS505N, initially
discovered in association with inherited familial
thrombocytosis) have also been reported.63
MPLW515L induced both cytokine-independent
growth and Tpo hypersensitivity in cell lines, result-
ing in constitutively activated JAK-STAT/ERK/Akt
signaling pathways,64 and caused a PMF-like disease
in mice.17 At variance with the JAK2V617F trans-
plantation model, the disease induced by
MPLW515L was characterized by a rapidly fatal
course, marked thrombocytosis, leukocytosis, hepa-
tosplenomegaly, and bone marrow fibrosis, all remi-
niscent of PMF.17 Interestingly in some patients,
multiple MPL mutations or the coexistence with
JAK2V617F allele were described.60,62,65
The gene encoding for the receptor of platelet-
derived growth factor A (PDGFRA) is involved in at
least four different genetic abnormalities associated
with eosinophilia.66 The most frequent and best
characterized abnormality is due to a karyotypically
occult microdeletion at chromosome 4q12, where
PDGFRA is located, resulting in a chimeric FIP1L1-
PDGFRA fusion gene (Fig. 1B).10 The latter encodes
for an aberrantly activated tyrosine kinase as the
consequence of disruption of the autoinhibitory ac-
tivity encoded by PDGFRA exon 12, where the
breakpoint is located; this constitutively active ty-
Myeloproliferative Neoplasms
174 CA: A Cancer Journal for Clinicians
 by on M
ay 6, 2009 (©American Cancer Society, Inc.) 
ca
o
nline.am
cancersoc.org
D
ow
nloaded from
 
rosine kinase drives autonomous eosinophil progen-
itor proliferation,67 possesses transforming properties
in vitro, and induces a myeloproliferative disorder
with extensive eosinophil proliferation when ex-
pressed in transplanted mice.68 The fusion gene has
been demonstrated at the level of hematopoietic stem
cell compartment.69 Also the Beta type of PDGFR
has been reported as being involved in rearrange-
ments70 associated with imatinib-responsive eosino-
philia.71 The PDGFRB is located at chromosome
5q31-32 and may fuse with different partners. One of
the most common is the ETV6/TEL gene on chro-
mosome 12p13, which encodes for a transcription
factor with nonredundant roles in normal hemato-
poiesis.72 The fusion protein constitutively activates
the cellular pathways normally associated with PDG-
FRB signaling73 and has transforming properties
when expressed in cell lines.
A D816V mutation located in the catalytic domain
of the tyrosine kinase receptor c-Kit occurs in sys-
temic mastocytosis (Fig. 1B).11,74 c-Kit is the recep-
tor for stem cell factor, a key cytokine involved in the
generation and differentiation of mast cells from
primitive hematopoietic progenitors; it is encoded by
kit, located at chromosome 4q12. Additional activat-
ing kit mutations other than D816V have also been
described in SM, acute leukemia,75 gastrointestinal
stromal cell tumors (GIST), and germ cell tumors.76
The D816V and other homologous mutations induce
growth factor independent growth and cell differen-
tiation in mast cell lines through activation of
STAT5/PI3K/AKT signaling pathways and a phe-
notype resembling human SM in murine models.77
Classification of Myeloproliferative
Neoplasms
The 2008 WHO classification for myeloid neo-
plasms, which incorporates novel information de-
rived from molecular discoveries in BCR-ABL neg-
ative “classic” myeloproliferative states and clonal
eosinophilic disorders, includes five major entities
(Table 2)8 as follows: the Acute Myeloid Leukemia
(AML) and the Myelodysplastic Syndromes (MDS)
with their different subtypes, whose listing is outside
the scope of this review; the Myeloproliferative Neo-
plasms (MPN); the category of overlapping Myelo-
dysplastic/Myeloproliferative Neoplasms (MDS/
MPN); and the Myeloid Neoplasms associated with
eosinophilia and specific molecular abnormalities.
AML is defined by the presence of either20% blast
cells in the bone marrow and/or peripheral blood or
certain characteristic cytogenetic abnormalities.78
The MDSs are recognized and distinguished from
MPN primarily on the basis of the presence of tri-
lineage dyshematopoiesis in the absence of monocy-
tosis in both bone marrow and peripheral blood.78
A “nontrivial” formal modification in the 2008
WHO classification has been the substitution of the
attribute “neoplasm” for “disease”. In fact, notwith-
standing the analysis of the X chromosome inactiva-
tion pattern in informative females and other cyto-
genetic and/or molecular findings that established
both “classic” and “nonclassic” myeloproliferative dis-
orders as being clonal stem cell disorders,79-89 and the
finding that evolution to AML is part of their natural
history,90 the neoplastic nature of these conditions
TABLE 2. The 2008 World Health Organization
Classification for Myeloid Neoplasms
1. Acute myeloid leukemia (AML) and related precursor neoplasms
2. Myelodysplastic syndromes (MDS)
3. Myeloproliferative neoplasms (MPN)
3.1. Chronic myelogenous leukemia (CML), BCR-ABL1 positive
3.2. Polycythemia vera (PV)
3.3. Essential thrombocythemia (ET)
3.4. Primary myelofibrosis (PMF)
3.5. Chronic neutrophilic leukemia (CNL)
3.6. Chronic eosinophilic leukemia, not otherwise classified (CEL-NOS)
3.7. Mastocytosis
3.8. Myeloproliferative neoplasm, unclassifiable (MPN-u)
4. Myelodysplastic/Myeloproliferative neoplasms (MDS/MPN)
4.1. Chronic myelomonocytic leukemia (CMML)
4.2. Juvenile myelomonocytic leukemia (JMML)
4.3 Atypical chronic myeloid leukemia, BCR-ABL1 negative
4.4. Myelodysplastic/myeloproliferative neoplasm, unclassifiable
4.5. Refractory anemia with ring sideroblasts associated with marked
thrombocytosis
5. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities
of PDGFRA, PDGFRB, or FGFR1
5.1. Myeloid and lymphoid neoplasms associated with PDGFRA
rearrangement
5.2. Myeloid neoplasms with PDGFRA rearrangement
5.3. Myeloid and lymphoid neoplasms with FGFR1 abnormalities
From Tefferi A and Vardiman JW.136
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has been mostly dismissed until recently. This belief
has most likely represented one of the reasons for the
traditionally poor interest in these neoplasms by can-
cer surveillance programs, agencies granting research
support, or pharmaceutical companies.
The four “classic” MPNs (ie, CML, PV, ET, and
PMF) should be distinguished from the other “non-
classic” MPNs, which include chronic neutrophilic
leukemia (CNL), chronic eosinophilic leukemia-not
otherwise specified (CEL-NOS), systemic mastocy-
tosis (SM), and unclassifiable forms of MPN.91
CML presents very unique characteristics, and it will
not be further discussed herein; recent excellent re-
views on molecular and therapeutic issues have been
published.92-94
Chronic Neutrophilic Leukemia
CNL is a rare disorder of elderly people characterized
by neutrophilic leukocytosis (greater than 25 109/L)
made up of greater than 80% mature granulocytes,
splenomegaly, and an absence of the Philadelphia chro-
mosome/BCR-ABL fusion gene. Bone marrow biopsy
reveals hyperplasia of granulocytic lineage without in-
volvement of other series, and there is an absence of
fibrosis or myelodysplastic features. Given the potential
for evolution to acute leukemia or progressive refractory
leukocytosis, allogeneic stem cell transplantation may be
appropriate for younger patients.95,96
Chronic Eosinophilic Leukemia and
Hypereosinophilic Syndrome
Patients who have a persistent absolute eosinophil
count of at least 1.5  109/L, after exclusion of re-
active eosinophilias or other hematologic disorders,
suffer from one of the different forms of primary
eosinophilia.97,98 Many patients with nonclonal
forms of eosinophilia fall within the category of “id-
iopathic” hypereosinophilia; the possibility of a T-
cell mediated eosinophilia, generally via increased
levels of interleukin-5, can be ruled out with ade-
quate studies of T-cell immunophenotyping and T-
cell receptor antigen gene rearrangement.99 Con-
versely, finding a cytogenetic or molecular
abnormality would indicate a clonal, myeloprolifera-
tive, eosinophilic disorder.98 Diagnosis of CEL not
otherwise (molecularly) specified rests on the dem-
onstration of a cytogenetically abnormal proliferation
of eosinophilic precursors with a myeloblast count of
5% to 19% in the bone marrow or greater than 2% in
peripheral blood, usually accompanied by evidence of
organ damage.97 However, because of intrinsic diffi-
culties in establishing the presence of a clonal disor-
der when the most frequent molecular abnormalities
associated with eosinophilia are lacking (see below),
it is likely that many forms of CEL-NOS actually fall
improperly within the idiopathic hypereosinophilic
syndrome (HES) category.100 Documentation of tar-
get organ damage is necessary for a patient to be
considered as suffering from HES. Clinical manifes-
tations are related to eosinophilic infiltration of target
tissues and may range from almost asymptomatic
disease to fatal endomyocardial tissue fibrosis. Bone
marrow biopsy reveals eosinophilia without involve-
ment of other cell lines, absence of immature myeloid
cells or dysplasia, and a normal number of mast cells.
Therapy is based on corticosteroids as first-line ther-
apy, interferon-alpha, or hydroxyurea in refractory or
steroid-dependent patients; some patients may re-
spond to imatinib.101 Use of monoclonal antibodies
to interleukin-5 (mepolizumab)102 or CD52 (the re-
ceptor for interleukin 2; alemtuzumab)103 has pro-
duced appreciable results in refractory cases.66
Mast Cell Disease
Mast cell disease, which is defined by tissue infiltra-
tion by abnormal mast cells, can be broadly classified
into cutaneous mastocytosis (CM) and systemic mas-
tocytosis (SM); the latter might have an indolent or
an aggressive clinical course depending on the ab-
sence or presence, respectively, of impaired organ
function.104 Life expectancy is nearly normal in in-
dolent forms of SM but is significantly shortened in
aggressive SM. The bone marrow is almost univer-
sally involved in SM and is characterized by dense,
multifocal aggregates of morphologically and immu-
nophenotypically abnormal mast cells, preferentially
in a perivascular location, and is often accompanied
by increased eosinophils. Serum levels of tryptase are
typically high and represent a clinically useful dis-
ease-related marker. By using adequately sensitive
molecular techniques (such as allele-specific poly-
merase chain reaction [PCR] amplification of DNA)
and mast cell-enriched sources (such as bone marrow
aspirate or biopsied lesional material), the kit D816V
mutation is detected in virtually all patients with
Myeloproliferative Neoplasms
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SM.105 In addition to its diagnostic value, clinical
relevance of searching the D816V kit mutation lies in
the almost universally reported refractoriness of mu-
tated patients to imatinib.106 Conversely, rare pa-
tients with other mutations that are located in the
c-Kit juxtamembrane portion may respond to treat-
ment with imatinib. Treatment of systemic mastocy-
tosis is highly individualized and largely palliative,
aiming to prevent or reduce symptoms due to mast
cell degranulation or organ infiltration. Therapeutic
options are represented by interferon-alpha or cyto-
toxic drugs, such as cladribine, but clinical responses
are limited.107
Myelodysplastic/Myeloproliferative
Neoplasms
MDS/MPN neoplasms are defined by simultaneous
presence of both myelodysplastic and myeloprolifer-
ative features that exclude them from being catego-
rized as either MDS or MPN alone.108 MDS/MPN
neoplasms comprise chronic myelomonocytic leuke-
mia (CMML), juvenile MML (of pediatric interest
and, thus, not further discussed here), atypical CML,
and unclassified MDS/MPN. The clinical and he-
matologic presentation of MDS/MPN is pleomor-
phic, with cytopenia and dysplasia of any cell lineage
eventually becoming associated with elevated leuko-
cyte or platelet count. Symptoms may be attributed
to cytopenias (anemia, infections, hemorrhage)
and/or to myeloproliferation (organomegaly, sys-
temic symptoms, cardiovascular events).91 The mo-
lecular basis of these disorders is largely unknown,
apart from the involvement of ras pathway with mu-
tations of RAS109 in CMML and PTPN11110 muta-
tions in JMML, or the uncommon presence of
JAK2V617F mutation.111 Therefore, diagnosis relies
on a combination of hematological, clinical, and his-
tological criteria.
The typical manifestation of CMML is peripheral
blood monocytosis greater than 1  106/L and a
percentage of monocytes in the white blood cell
count of greater than 10%. Monocytes may or may
not display signs of dysplasia, but the percentage of
immature monocytes (promonocytes) and mono-
blasts in peripheral blood is less than 20%. Both
monocytic and granulocytic hyperplasia are found in
the bone marrow with a total blast count of less than
20%; signs of erythroid and megakaryocytic dysplasia
are variably present. Random cytogenetic abnormal-
ities can be discovered in 20% to 40% of these pa-
tients. The prognosis is unfavorable with a median
survival of only 2-4 years; a major determinant of
survival is the percentage of blood and bone marrow
blasts.91 Hypomethylating agents like decitabine and
azacitidine are now approved for treating CMML.112
Response rate varies from 10% to 30%, depending on
the drug and the schedule used, with best results
reported for decitabine when a high-dose intensity
regimen is used.113-115 Treatment is well tolerated
with relatively few nonmyelosuppressive complica-
tions and has become a valuable therapeutic option
for a disease where just a few years ago the standard
of care was merely supportive.
Atypical CML is a rare, aggressive disorder with a
median survival of 1-2 years and usually affects el-
derly patients. It presents features typical of classic
CML, but unlike classic CML, it is BCR/ABL neg-
ative and displays manifest signs of dysgranulopoiesis
with nuclear aberrations and cytoplasmic hypogranu-
lation.108 JAK2V617F mutation is absent.116 The
bone marrow is hypercellular; dysplasia of myeloid
lineage with less than 20% blasts is a constant feature,
whereas other lineages are variably involved. The
disease terminates in AML in up to 40% of these
patients.
Refractory anemia with ring sideroblasts and
thrombocytosis (RARS-T) is a rare syndrome char-
acterized by anemia with dyserythropoiesis and ring
sideroblasts in the bone marrow, associated with
thrombocytosis and increased number of large
megakaryocytes. These morphologic features of
megakaryocytes are distinct from the appearance typ-
ically associated with the 5q- abnormality.117 A high
proportion of patients have the JAK2V617F muta-
tion,118 although a few harbor the MPL mutation.119
RARS-T is a disease with a relatively good progno-
sis,120 and it shares many aspects with classic MPN.
Finally, when myelodysplastic and myeloprolifer-
ative features simultaneously present in bone marrow
aspirate do not fit into any of the previous categories,
and after any known molecular or cytogenetic abnor-
mality is excluded, the disorder is defined as MDS/
MPN unclassifiable, with a comment describing the
atypical features.108
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Myeloid Neoplasms Associated with
Eosinophilia and Specific Molecular
Abnormalities
Both the alpha (PDGFRA) and beta (PDGFRB)
types of platelet-derived growth factor receptor
(PDGFR) genes may be involved in genetic abnor-
malities associated with eosinophilia.121 Eosinophilia
associated with FIP1L1-PDGFRA rearrangement
has a strikingly male predominance. In addition to an
expanded eosinophilic lineage, the bone marrow of-
ten contains an increased number of mast cells that,
together with findings of raised serum levels of
tryptase, sometimes make problematic the differen-
tial diagnosis with SM.122 However, at variance with
kit D816V-mutated forms of SM, presence of the
FIP1L1-PDGFRA mutation reliably predicts hema-
tologic and molecular remission when imatinib is
used at doses lower than those used for CML (100
mg daily is generally efficacious).123 The rate of com-
plete molecular response may be as high as 95%, and
a prospective multicenter study showed it to be stable
and durable during a median follow-up of 25 months
but to be dependent on treatment continuation. In
three patients who discontinued imatinib, molecular
negativity was lost and then regained after imatinib
was resumed.124 A definitely lower proportion of
patients with imatinib-responsive eosinophilia have
rearrangements involving the PDGFRB gene. Fi-
nally, translocations involving the fibroblast growth
factor receptor-1 gene (FGFR1), which is located at
chromosome 8p11, and several different gene part-
ners are at the basis of the “8p11 myeloproliferative
syndrome”.125 This is also called “stem cell leukemia/
lymphoma syndrome” because of the clinical pheno-
type that is characterized by features of both lym-
phoma and eosinophilic myeloproliferation. The
disease results from constitutive activation of the ty-
rosine kinase domain of FGFR1 after its juxtaposition
with any partner gene. Prognosis is very poor with most
patients progressing to overt AML or lymphoblastic
lymphoma with 1-2 years of diagnosis.126
The “Classic” Myeloproliferative
Neoplasms
Among classic MPNs, PV and ET are relatively
indolent disorders,127 resulting in a modest reduction
of lifespan compared with a control population; how-
ever, most patients ultimately suffer from one or
more severe and potentially fatal complications di-
rectly attributable to the disease. Conversely, PMF
has a severe course in most cases, and survival is
significantly affected. The three clinical entities share
several common features,6 such as their origin in a
multipotent hematopoietic stem cell, a relatively nor-
mal cellular maturation, a striking overlap in clinical
presentation (apart from PMF, which has its own
peculiar manifestations), and in cases of PV and ET,
the propensity to evolve into post-polycythemic or
post-thrombocythemic myelofibrosis (or less fre-
quently each into the other), and the possibility to
transform into AML.90
Epidemiology
Classic MPNs are among the most frequent hema-
tologic neoplasms, usually affecting the adult elderly
population; however, they can also be found in chil-
dren, and in this instance, they raise specific diag-
nostic and management issues128,129 that are beyond
the scope of this review. A recent study,130 based on
the North American Association of Central Cancer
Registries (NAACCR) encompassing 82% of total
US population, reported an average 2001-2003 an-
nual age-adjusted incidence rate of 2.1 per 100,000
and estimated that there were 6,328 new cases in the
total US population in 2004. Furthermore, because
of their relatively smooth clinical course, it is likely
that many classic MPN cases actually go undetected
or are not reported to registries. Advanced age, male
sex, and white race were identified as risk factors.
Among individuals aged 80 years or older, the rate was
as high as 13.3 per 100,000. Familial clustering of these
disorders is known, and even before the discovery of
JAK2V617F mutation, 131 this observation led to a
suggestion of predisposition allele(s).132 This hypoth-
esis gained substantial support from a large study
recently completed in Sweden.133 Relatives of pa-
tients with MPN had a 5.7 relative risk (RR) of
having PV, an RR 7.4 for ET, and an RR of 7.5 for
unclassified forms of MPN, together with a border-
line increased RR of CML. The higher risk observed
among siblings would suggest a model of recessive
inheritance, although whether presentation of disease
occurs at an even younger age than in parents is
debatable.133,134 Accordingly, thorough investigation
of family history is mandatory in the initial workup of
patients with classic MPN, and appropriate counsel-
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ing should be provided. The coexistence of different
clinical entities and of JAK2V617F-positive and
JAK2V617F-negative diseases in the same family is
noteworthy.131,134,135
Diagnosis
Because of similarities with reactive forms character-
ized by an increased count of mature peripheral blood
cells on one side, and the significant phenotypic
overlapping among them on the other, diagnosis of
different MPNs has traditionally been challenging;
the availability of the new molecular markers is ex-
pected to facilitate diagnosis (Table 3). As a matter of
fact, molecular genotyping is integral to the 2008
WHO diagnostic criteria,136 and tests for JAK2 or
MPL mutation already have become a standard tool
in the diagnostic work up of MPN (Fig. 2).137 In fact,
detection of one of these mutations unequivocally
establishes by itself the presence of a clonal MPN and
rules out the possibility of reactive erythrocytosis,
thrombocytosis, or myelofibrosis. Unfortunately,
they are of no help in distinguishing among the
different forms of MPNs, although JAK2 exon12
FIGURE 2. Rationale for using JAK2V617F genotyping in the diagnostic
work-up of suspected MPN. See text for details.
TABLE 3. 2008 WHO Diagnostic Criteria for “classic” MPN
CRITERIA POLYCYTHEMIA VERA ESSENTIAL THROMBOCYTHEMIA PRIMARY MYELOFIBROSIS
Major criteria 1. Hgb 18.5 g/dL (men) or 16.5 g/dL
(women)
or Hgb or Hct  99th percentile of
reference range for age, sex, or
altitude of residence
or Hgb 17 g/dL (men) or 15 g/dL
(women) if associated with a
documented and sustained increase
of 2 g/dL from baseline that
cannot be attributed to correction of
iron deficiency
or elevated red cell mass 25% above
mean normal predicted value
2. Presence of JAK2V617F or similar
mutation
1. Sustained platelet count 450 x 109/L
2. BM showing proliferation mainly of the
megakaryocytic lineage with increased
numbers of enlarged, mature
megakaryocytes. No significant increase or
left-shift of neutrophil granulopoiesis or
erythropoiesis
3. Not meeting the WHO criteria for PV,
PMF, CML, or MDS or other myeloid
neoplasm
4. Demonstration of JAK2V617F or other
clonal marker
or no evidence of reactive thrombocytosis
1. Megakaryocyte proliferation and atypia*
accompanied by either reticulin and/or collagen
fibrosis
or In the absence of reticulin fibrosis, the
megakaryocyte changes must be accompanied
by increased marrow cellularity, granulocytic
proliferation and often decreased
erythropoiesis (ie, pre-fibrotic cellular-phase
disease)
2. Does not meet WHO criteria for CML, PV, MDS,
or other myeloid neoplasm
3. Demonstration of JAK2V617F or other clonal
marker
or no evidence of reactive marrow fibrosis
Minor criteria 1. BM showing hypercellularlity for age
and trilineage growth (panmyelosis)
— 1. Leukoerythroblastosis
2. Subnormal serum Epo level 2. Increased serum LDH
3. EEC growth 3. Anemia
— 4. Palpable splenomegaly
Diagnostic
combinations
Both major criteria  1 minor criterion
or first major criterion  2 minor
criteria
All 4 criteria must be met All 3 major criteria  2 minor criteria
WHO indicates World Health Organization; MPN, myeloproliferative neoplasm; CML, BCR-ABL1 chronic myelogenous leukemia; PV, polycythemia vera; PMF, primary
myelofibrosis; MDS, myelodysplastic syndrome; BM, bone marrow biopsy specimen; Epo, erythropoietin; EEC, endogenous erythroid colonies; LDH, lactate dehydro-
genase.
*Small to large megakaryocytes with an aberrant nuclear/cytoplasmic ratio and hyperchromatic, bulbous, or irregularly folded nuclei and dense clustering.
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mutations have not yet been reported outside PV,
and no patient with PV has been found to harbor an
MPL mutation.
In patients with evidence of increased red cell
mass, according to WHO criteria,136 demonstration
of JAK2V617F mutation allows a diagnosis in greater
than 95% of cases, as less than 2% of PV patients
harbor JAK2 exon 12 abnormalities.16 It is debated
whether a diagnosis of PV can still be tenable in the
absence of JAK2 mutation.138,139
The compelling criterion for a diagnosis of ET is
a sustained platelet count of greater than 450  109/
L. Notably, this value is lower than the one originally
used by the 2001 WHO classification system
(600  109/L),5 because the latter might have led to
inadvertently overlooking classic ET cases with a
lower platelet count.140 This assumption is supported
by the discovery of the JAK2V617F mutation in some
subjects who have a platelet count lower than
600  109/L.47 Diagnosis of ET requires exclusion
of reactive thrombocytosis141,142 as well as of other
MPNs that present with thrombocytosis. In partic-
ular, exclusion of CML with FISH or PCR analysis
for BCR-ABL rearrangement is mandatory. Positivity
for JAK2V617F or MPL mutation cumulatively ac-
count for 60% to 70% of ET cases. Therefore, the
assessment of bone marrow morphology remains key
to the diagnosis of ET; bone marrow cellularity is
normal or slightly increased, with abundance of large,
mature-appearing megakaryocytes devoid of mor-
phological abnormalities and generally dispersed
throughout the biopsy. This appearance is distinct
from both the panmyelosis typical of PV or the
predominant granulocytic hyperplasia with highly bi-
zarre megakaryocytes, often found in abnormally
tight clusters, with aberrant nuclear to cytoplasmic
ratio and hyperchromatic, bulbous, or irregularly
folded nuclei that are found in PMF, even in initial
stages without overt fibrosis.137,143
Bone marrow histology is required for the diagno-
sis of PMF. Although advanced reticulin or colla-
genic fibrosis is typically associated with classic stages
of PMF, some degree of reticulin fibrosis can be
found as well as in PV, or more occasionally in ET.
Therefore, fibrosis by itself is not synonym for PMF,
and diagnosis of PMF can be made even in the
absence of overt fibrosis.8 Also the leukoerythroblas-
tic features of blood smears, with immature myeloid
precursors, nucleated red cells, and abnormally
shaped erythrocytes (tear-drop cells), is very charac-
teristic, but not diagnostic, of PMF. CML should be
ruled out through BCR-ABL rearrangement analysis,
while finding a positive JAK2V617F or MPL muta-
tion allows exclusion of reactive forms of myelofibro-
sis (such as in infectious or inflammatory processes,
metastatic cancer, and lymphoid disorders). Some
cytogenetic abnormalities, such as del(13)(q12;q22),
are frequently encountered and may be diagnostically
specific in this context.144 Anemia, palpable spleno-
megaly, and raised lactate dehydrogenase levels are
additional diagnostic criteria.8
Clinical Course and Risk Stratification
Thrombosis, hemorrhage, evolution to post-polycy-
themic or post-thrombocythemic myelofibrosis, and
AML transformation represent the most clinically
relevant issues in the course of classic MPN.145-147
Most thrombotic events occur at or in the two years
before diagnosis.148 However, epidemiologic infer-
ence from the European Collaboration on Low-dose
Aspirin in Polycythemia (ECLAP) study146,149 and
the UK Medical Research Council Primary Throm-
bocythemia-1 (MRC PT-1) study150 suggested that
the cumulative rate of thrombosis during the disease
course ranged from 2.5% to 5.0% and from 1.9% to
3% per patient-year in PV and ET, respectively,
depending on whether the patient was in a low-risk
or high-risk category.146,150 In a large retrospective
study of PV or ET patients who had suffered from a
previous cardiovascular event, the calculated recur-
rence rate was 5.6% patient-year with a cumulative
probability of 49.9% at 10 years.151 Arterial throm-
bosis accounts for 60% to 70% of all cardiovascular
events and includes acute myocardial infarction, isch-
emic stroke, and peripheral arterial occlusion. Events
involving the venous system, more common among
PV patients, are represented by lower extremity deep
venous thrombosis, pulmonary embolism, and
splanchnic vein thromboses (SVT, which includes
portal vein thrombosis, mesenteric thrombosis, and
thrombosis of the hepatic veins causing Budd-Chiari
syndrome). The prevalence of SVT is unusually high
among MPN patients152; however, diagnosis is often
complicated by the hemodilution resulting from hy-
persplenism that makes blood cell counts unreliable,
in particular as concerns evidence of increased red cell
mass necessary for the diagnosis of PV.153 Recent
data indicate that at least 40% of patients with SVT
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not attributable to other causes actually harbor the
JAK2V617F mutation; therefore, JAK2V617F geno-
typing represents a first-line test for these condi-
tions.154,155 Occasional SVT patients harboring MPL
mutation have also been reported.156 Conversely, in-
volvement of the microcirculatory system is more
typically associated with ET and manifests as eryth-
romelalgia (a rare disorder characterized by burning
pain, warmth, and redness of the extremities due to
arteriolar fibrosis and occlusion with platelet
thrombi, typically aspirin-sensitive),157 transient
ischemic attacks, visual or hearing transitory defects,
recurrent headache, and peripheral paresthesia; how-
ever, because of the lack of objective diagnostic cri-
teria, true incidence of microvessel disturbances is
difficult to assess.158 Pathogenesis of thrombosis in
classic MPNs is multifactorial; rheologic abnormali-
ties due to increased red cell mass in PV, abnormal
function of platelets and their enhanced interaction
with leukocytes and endothelial cells, are all possible
contributing factors159; however, neither thrombocy-
tosis nor increased hematocrit (at least until 52%) are
clearly associated with occurrence of thrombosis.160
Mortality rate is age-dependently increased in PV,
being 1.6-fold and 3.3-fold higher than in the refer-
ence population in patients younger or older than 50
years, respectively.161 Conversely, survival of ET pa-
tients is reduced by about 2-fold compared with the
general population starting from the first decade after
diagnosis.162 Major causes of shortened survival in
PV or ET are represented by thrombotic events and
transformation to myelofibrosis or AML, which ac-
count for 41% and 13% of total deaths among 1,638
PV patients that were included in the observational
arm of the ECLAP study.146,163 An age of greater
than 60 years and leukocytosis were incorporated in a
predictive model for survival in ET that discrimi-
nated groups of patients with median survivals of 25,
17, and 10 years, respectively.162 Therefore, because
of the finding that thrombosis represents the most
common event that complicates the courses of PV
and ET, and eventually is the leading cause of death,
it seems appropriate to use this clinical endpoint as
the criterion for stratifying patients according to their
risk.164 Older age (greater than 60 years) and a pre-
vious history of thrombosis are standard risk factors
for thrombosis in both PV and ET (Table 4), which
have been validated in several studies.146,148,165 In the
presence of either of these, a patient is at high-risk,
whereas when neither of these is present, the disease
is low-risk. The role of generic cardiovascular risk
factors, such as hypertension, diabetes, hyperlipid-
emia, smoking, or genetic alterations of hemostatic
factors, is still controversial; however, patients who
present with any of these abnormalities are pruden-
tially considered to belong to an intermediate-risk
category,158,166 and both specific medical intervention
and correction of life style issues, particularly smok-
ing, should be aggressively pursued. Recent studies
have demonstrated that leukocytosis is an additional
independent risk factor for thrombosis,162,167,168 par-
ticularly for acute myocardial infarction in PV. Fur-
thermore, “low-risk” ET patients could be separated
into two categories with a respective overall preva-
lence of thrombosis of 55% and 20% depending on
the presence, or not, of an absolute leukocyte count
greater than 8.7  109/L.169 Finally, there is also
evidence that JAK2V617F mutated status in
ET,47,170,171 and a high V617F allelic burden in both
ET47,172 and PV172-173 are associated with increased
risk of thrombosis. Therefore, both leukocytosis and
JAK2V617F mutated status represent novel, power-
ful, disease-associated, risk factors; however, before
they are included in current risk stratification criteria
outlined in Table 4, they need validation in prospec-
tive studies.
Life expectancy in PMF is 31% lower than in an
age-matched and sex-matched population, with a
median survival of 5 years, although younger patients
may experience longer survival.161,174,175 Major causes
of death are represented by the sequelae of portal
hypertension or hepatic-splenoportal thrombosis,
thromboses in various anatomic sites, heart failure
due to splenic pooling, infections, pulmonary hyper-
tension, bleeding caused by thrombocytopenia or he-
mostatic defects, and transformation to AML.147
Prognostic staging systems for PMF have been de-
veloped that allow separation of patients with low-
TABLE 4. Risk-Stratification of Patients with Polycythemia
Vera or Essential Thrombocythemia
RISK CATEGORY
AGE >60 YEARS
OR HISTORY OF
THROMBOSIS
GENERIC CARDIOVASCULAR
RISK FACTORS
Low No No
Intermediate No Yes
High Yes Irrelevant
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risk and high-risk disease associated with signifi-
cantly different survival times (Table 5). The most
used “Lille score” includes anemia and abnormal leuko-
cyte count as variables and effectively distinguishes pa-
tients with survival times that range from 1-8 years.176
Stratification according to risk is of particular impor-
tance in younger patients who may potentially exploit
the curative efficacy of allogeneic hematopoietic stem
cell transplantation (HSCT). In this regard, “Cer-
vantes”175 and “Mayo” ad hoc scoring systems for pa-
tients aged younger than 55 years or 60 years have been
developed177 and represent useful instruments to aid
both physician and patient to make the most appropri-
ate therapeutic decision (Table 5). Presence of a
JAK2V617F mutated state independently predicted
leukemic transformation in a longitudinal prospective
series of PMF patients,178 whereas presence of
MPLW5151L/K mutation was associated with more
severe anemia.60 However, because of conflicting results
reported in similar studies,179 these markers need fur-
ther validation before being operationally incorporated
into prognostic systems.
Transformation to post-polycythemic or post-
thrombocytemic myelofibrosis represents the natural
evolution of PV and ET, occurring late in the clinical
course. The estimated rate is about 5% after 15 years
from diagnosis of PV,146 whereas data are scanty in ET.
Criteria for the diagnosis of evolution to myelofibrosis
have recently been proposed by the International
Working Group for Myelofibrosis Research and Treat-
ment (IWG-MRT; Table 6).180 Survival is probably
shortened by the development of myelofibrosis, and
may be predicted by hemoglobin level and platelet and
leukocyte counts according to a dynamic prognostic
model recently developed in PV patients.183
Evolution to AML occurred in 1.3% of PV patients
included in ECLAP study, at a median time of 8.4
years after diagnosis163; however, because of the short
follow up, a precise estimate cannot be made, and
information about ET is not yet available. Survival time
is dismal, less than 6 months, although recipients of
allogeneic HSCT may experience longer remission.184
Advanced age, elevated leukocyte count, and longer
disease duration were factors associated with increased
risk of leukemic transformation.163 An increased risk of
AML was reported in patients who were treated with
radioactive phosphorus or chlorambucil in the PVSG
trial.185 In addition, sequential or combined use of more
TABLE 5. Prognostic Scoring Systems Used for Risk Assessment in Patients with PMF
PROGNOSTIC SCORING SYSTEM PROGNOSTIC FACTORS
NO. OF PROGNOSTIC FACTORS BY RISK
CATEGORY
NO. OF MONTHS OF SURVIVAL BY RISK
CATEGORY
LOW INTERMEDIATE HIGH LOW INTERMEDIATE HIGH
All patients
Lille Hb 10 g/dL
WBC 4 or
30x109/L
0 1 2 93 26 13
Cervantes Hb 10 g/dL
PB Blasts 1%
Constitutional
symptoms
0-1 — 2-3 99 — 21
Mayo Hb 10 g/dL
WBC 4 or
30x109/L
Plt 100x109/L
Monocytes 1x109/L
0 1 2 173 61 26
Younger patients
Cervantes, aged 55 y Hb 10 g/dL
PB Blasts 1%
Constitut. symptoms
0-1 — 2-3 176 — 33
Dingli, aged 60 y Hb 10 g/dL
WBC 4 or
30x109/L
Plt 100x109/L
0 1 2-3 155 69 24
Constitutional symptoms included unexplained fever, night sweats, or weight loss of greater than 10% of baseline value in the last 6 months.
PMF indicates primary myelofibrosis; Hb, hemoglobin; WBC, white blood cell count; PB Blasts, percentage of blasts in peripheral blood smears; Plt, platelet count.
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than one chemotherapeutic agent, including hydroxy-
urea (HU), significantly increased the rate of evolution
to AML in PV patients in the observational arm of
ECLAP study.186
Management of Classic MPN
Over the years, there has been a shortage of clinical
studies specifically devoted to classic MPN. Most
available information derives from a limited number
of randomized clinical trials performed within na-
tional or international collaborative groups that in-
clude the Polycythemia Vera Study Group
(PVSG),165,186 the ECLAP study,146,149 the “Ber-
gamo trial,”187 and the PT-1 trial150; however, the
information they have provided represents the foun-
dation for current treatment indications189-192 as well
as the basis for future studies
(Table 7). Standardized criteria
for assessing clinical and hema-
tologic responses in PMF have
been published193,194 and will be
of particular relevance for evalu-
ation of novel molecularly target
drugs. Conversely, similar crite-
ria for patients with PV or ET
are still lacking.
Cytoreductive Therapy in PV
and ET
Treatment of patients with PV
or ET should adhere to the stan-
dard risk stratification outlined
above (Table 4). Phlebotomy is
the cornerstone of treatment in
low-risk patients with PV,
aimed at reaching and maintain-
ing a target hematocrit of less
than 45% in men and less than
42% in women, according to
standard recommendations.165
The ultimate goal of this prac-
tice is to limit availability of iron
to erythropoiesis, but often it
will cause symptoms due to se-
vere and prolonged iron defi-
ciency; fatigue is being recog-
nized as one major burden for
quality of life in patients with
PV.127 In fact, there is wide vari-
ability in opinions and attitudes among US and
non-US physicians concerning the optimal hemato-
crit target to be attained with phlebotomies.195 Con-
versely, high-risk patients should receive myelosup-
pressive therapy, eventually in association with
phlebotomy, and hydroxyurea (HU) is the drug of
choice (Table 7). HU is an antimetabolite that
prevents synthesis of DNA. It is also approved for
the treatment of sickle cell anemia because of its
capacity to reactivate synthesis of hemoglobin F,
resulting in a significant decrease of occlusive and
hemolytic events.196 Superiority of HU compared
with phlebotomy was suggested in a comparative
analysis of the PVSG in the 1980s,185 but no
randomized trial to address this issue has yet been
undertaken.
TABLE 6. Criteria for Establishing the Diagnosis of Evolution to Post-polycythemic
or Post-thrombocythemic Myelofibrosis According to IWG-MRT Criteria180
CRITERIA FOR POST-POLYCYTHEMIC MYELOFIBROSIS
Required criteria
1. Documentation of a previous diagnosis of polycythemia vera as defined by WHO criteria136
2. Bone marrow fibrosis grade 2-3 (according to the European classification181) or grade 3-4 (according
to standard classification182)
Additional criteria
1. Anemia (below the reference range for appropriate age, sex, and altitude considerations) or sustained
loss of either phlebotomy (in the absence of cytoreductive therapy) or cytoreductive treatment
requirement for erythrocytosis
2. A leucoerythroblastic peripheral blood picture
3. Increasing splenomegaly of 5 cm (distance of the tip of the spleen from the left costal margin) or
the appearance of a newly palpable splenomegaly
4. Development of 1 of 3 constitutional symptoms: 10% weight loss in 6 months, night sweats,
unexplained fever (37.5°C)
CRITERIA FOR POST-THROMBOCYTHEMIC MYELOFIBROSIS
Required criteria
1. Documentation of a previous diagnosis of essential thrombocythemia as defined by WHO criteria136
2. Bone marrow fibrosis grade 2-3 (according to the European classification181) or grade 3-4 (according
to standard classification182)
Additional criteria
1. Anemia (below the reference range for appropriate age, sex, and altitude consideration) and a 20
g/L decrease from baseline hemoglobin level
2. A leucoerythroblastic peripheral blood picture.
3. Increasing splenomegaly of 5 cm (distance of the tip of the spleen from the left costal margin) or
the appearance of a newly palpable splenomegaly
4. Increased LDH (above reference level)
5. Development of 1 of 3 constitutional symptoms: 10% weight loss in 6 months, night sweats,
unexplained fever (37.5°C)
Diagnosis is made on the basis of meeting all required criteria plus two additional criteria.
WHO indicates World Health Organization; LDH, lactate dehydrogenase.
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The use of low-dose aspirin in PV was exploited in
the ECLAP study that randomized 518 low-risk
patients in a double-blind, placebo-controlled trial.149
The primary study endpoint (cardiovascular death,
nonfatal myocardial infarction, nonfatal stroke, and
major venous thromboembolism) was significantly
lowered by aspirin (RR, 0.40; 95% confidence inter-
val [CI] 0.18 to 0.91; P  .02), with only a small,
nonsignificant increase of major hemorrhage (RR,
1.62; 95% CI, 0.27 to 9.71; P  .60); total and
cardiovascular mortality were also reduced by 46%
and 59%, respectively. Therefore, in the absence of a
history of major bleeding, allergy to the drug or
severe asthma, or gastric intolerance, low-dose aspi-
rin (100 mg daily) is recommended regardless of risk
category for all patients with PV.149
Low-risk patients with asymptomatic ET do not
need therapy, although high-risk patients have the
same indications for the use of HU as patients with
PV.197 In the “Bergamo trial,” which randomized 114
high-risk patients to HU versus no treatment, the
percentage of patients who developed thrombosis
decreased from 24% to 3.6%.188 HU was also superior
to anagrelide, a nonmyelosuppressive platelet-lower-
ing drug, in preventing arterial thrombosis in the
randomized MRC-PT-1 trial, which included 809
high-risk patients, although venous thrombosis was
reduced in the anagrelide arm.54 Interestingly,
JAK2V617F-positive patients had a better response
and required lower doses of HU to control throm-
bocytosis compared with patients who did not have
this mutation.54 The target level at which the platelet
count should be maintained with therapy in high-risk
patients is currently set at 400-450  109/L, but this
is not based on evidence.197,198 Also, there is little
rationale for the use of cytoreductive treatment to
reduce extreme thrombocytosis (platelet count
greater than 1,000  109/L) in an otherwise low-
risk, asymptomatic patient.199
Unlike PV, the safety and effi-
cacy of low-dose aspirin use for
ET has not formally been
proven, but most patients in in-
termediate-risk or high-risk cat-
egories are currently advised to
use the drug. Higher doses, up
to 500 mg daily, may be required
for acute symptoms because of
microvascular disturbances, in
particular erythromelalgia. Conversely, extreme
thrombocytosis is considered a contraindication for
aspirin use because of a possibly increased bleeding
tendency due to acquired Von Willebrand dis-
ease.158,200-202
There has been some debate about potential leuke-
mogenicity of HU, but although current evidence does
not attribute to the drug a definite risk in this regard, it
is appropriate to reserve HU use for patients at high risk
of developing complications and in whom benefits ex-
pected from treatment overcome potential unwanted
effects. Actually, transformation to AML is considered
part of the natural history of MPN.186
Noncytotoxic Drugs for PV and ET
Interferon-alpha (IFN-), a nonleukemogenic agent,
has multiple potential activities against hematopoietic
progenitor cell proliferation and differentiation which
may justify its use in the youngest of patients with PV
and ET. However, tolerance is often poor because of
acute and chronic side effects that cause discontinuation
of the drug in one-third of patients. IFN- has been
shown to effectively reduce the hematocrit or platelet
count to a target level in the majority of cases,203,204 and
no thrombohemorragic events were recorded among 55
patients with PV who were followed for a median of 13
years.205 Progressive decrease of JAK2V617F burden
has been suggested in one study,206 whereas changes
were minimal in another study.207 Notably, a recent,
phase 2, multicenter study that used pegylated-IFN-
in 40 patients with PV reported complete molecular
remission in 7 of these patients.208 Finally, because
IFN- is not teratogenic and does not cross the pla-
centa, it is recommended whenever there is the need for
cytoreduction during pregnancy, according to current
guidelines.209
Anagrelide has widely been used to control platelet
count in patients with ET in all risk categories210; the
TABLE 7. Risk-Oriented Therapy in Polycythemia Vera (PV) and Essential
Thrombocythemia (ET)
RISK CATEGORY RISK FACTORS PV ET
Low Age 60 y and no prior
cardiovascular event Phlebotomies plus low-dose
aspirin
Nil, or low-dose aspirin
(no consensus)
Intermediate Generic cardiovascular
risk factors
Low-dose aspirin (no
consensus)
High Age 60 y and/or prior
cardiovascular event
MyelosuppressionPhlebotomies Myelosuppression
Low-dose aspirin Low-dose aspirin
Myeloproliferative Neoplasms
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majority of patients achieved adequate control of
thrombocytosis, although cardiovascular side effects
(mainly palpitations and headache, less frequently
congestive heart failure) may require early discontin-
uation of treatment.211,212 The drug is considered
devoid of any leukemogenic potential, but it should
not be prescribed during pregnancy. On the basis of
results of the PT-1 trial, anagrelide is not recom-
mended in high-risk patients as an alternative to HU,
and its rationale in otherwise low-risk or intermedi-
ate-risk patients should be carefully evaluated case by
case.213 However, according to recently published
guidelines,214 anagrelide could be successfully used in
platelet count control in patients with PV or ET who
are refractory and/or resistant, or who show poor
tolerance, or who develop side effects to HU.
Management of PMF
The only approach that has resulted in a prolongation
of survival time in PMF and has the potential to be
curative is allogeneic HSCT.215 At present, it should be
reserved for patients with high-risk disease after careful
clinical evaluation and thorough patient counseling,
particularly considering the option of inclusion in trials
with innovative drugs. Bothmyeloablative and reduced-
intensity conditioning regimens have been used, with
similar efficacy in terms of survival (3-year event-free
survival in the range of 50% to 60%) but lower mortality
rate with the use of the latter in older patients.216
Therefore, a myeloablative strategy may be considered
as the most appropriate for younger patients, whereas
the reduced-intensity regimen would be the best for
older patients. Furthermore, in patients who relapse
after HSCT, a graft-versus-myelofibrosis effect could
be demonstrated after donor-lymphocyte infusion with
a remarkable reduction of bone marrow fibrosis.217,218
Factors that have been reported as having a favorable
impact on overall survival after HSCT include a con-
ditioning regimen with busulfan/cyclophosphamide,
younger age, high platelet count, low comorbidity in-
dex, low risk according to the Dupriez score, normal
karyotype, hemoglobin of greater than 100 g/L, absence
of circulating blasts, and absence of osteosclerosis.219-221
The usefulness of pretransplant splenectomy still re-
mains controversial.215,222,223
Given that a conventional drug therapy does not
significantly modify disease course and is largely in-
effective, it is reserved for patients who present
either with symptomatic anemia or splenomegaly.
Androgens,224 prednisone,224 erythropoiesis-stimulat-
ing agents,225-227 and danazol228,229 are all variably used
with measurable effect in a few patients. Low-dose
thalidomide in combination with prednisone improves
anemia or thrombocytopenia in 30% to 50% of cas-
es.230-234 Lenalidomide, a thalidomide analog, has pro-
duced excellent and durable responses in the relatively
infrequent PMF patients who have the del(5q) abnor-
mality,235 and it can be recommended as first-line ther-
apy in this patient subset. When there is the need to
control excessive myeloproliferation, ie, leukocytosis,
thrombocytosis, or progressive splenomegaly, HU is the
current drug of choice.236 Several other drugs, including
busulfan,237 melphalan,238 and 2-chlorodeoxyade-
nosine,239 have been used particularly in HU-refractory
patients, but results are generally dismal. Splenectomy
has a role for alleviating mechanical symptoms due to
extreme splenomegaly and can also ameliorate anemia
in approximately 25% of transfusion-dependent pa-
tients.240 However, splenectomy in PMF bears an ap-
proximately 10% procedure-related mortality, and it
should be performed by experienced surgeons. Further-
more, up to 25% of patients present with accelerated
hepatomegaly and extreme thrombocytosis after sple-
nectomy, and these patients require further cytoreduc-
tion.240,241 Splenic irradiation is reserved for patients
who cannot undergo splenectomy for any reason, but
the efficacy of this therapy is poor, and subsequent
cytopenias are often severe. Conversely, radiation ther-
apy has a defined role in the treatment of nonhepato-
splenic extramedullary hematopoiesis, such as in cases
of spinal cord compression by foci of eterotopic hema-
topoiesis.242-245
Prospect for Molecularly Targeted Therapy in
Classic MPN
The involvement of JAK-STAT pathways in most pa-
tients who have classic MPN and harbor mutations in
JAK2 or MPL and the experimental evidence that sug-
gests that the same signaling abnormalities may be at
the basis of mutation-negative patients20 are behind
active efforts to develop anti-JAK2 drugs. Many mol-
ecules have undergone preclinical testing, in vitro and
also in vivo, and some have already been introduced into
clinical trials.246-252 A very incomplete list of molecules
that may or may not have selective anti-JAK2 activity is
reported in Table 8. Concerning selective JAK2 inhib-
itors, we have listed only those that are already in
clinical trials or whose activity has been demonstrated in
CA CANCER J CLIN 2009;59:171-191
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JAK2V617F-mutated murine models (TG101348).248
Among these, INCB018424, XL019, CEP-701, and
TG101348 are currently undergoing clinical trials in
patients with advanced stages of PMF, post-PV/ET
myelofibrosis, PV, and JAK2V617F-positive ET.253-256
Preliminary results have been encouraging in terms of
activity against splenomegaly and constitutional symp-
toms,253 with minimal toxicity. Although the number
of patients treated until now is less than 100 with any
single drug and, thus, prevents us from making any
definitive comment, the hope that this molecularly tar-
geted approach may finally result in improving quality
of life and possibly the chance of cure for patients with
classic MPN is enormous.
Patient Resources
During the last few years, we have witnessed a re-
newed interest in the MPN field among scientific
communities and pharmaceutical companies; at the
same time, the patient community is growing in
awareness and strength. There are several focused
resources for patient information and support that
include the Myeloproliferative Disorders Research
Consortium (MPD-RC, an international research
consortium funded by the National Cancer Institute;
http://www.mpd-rc.org), theMyeloproliferative Dis-
orders Foundation (committed to promoting focused
research and international expert cooperation and
also devoted to patient education and support; http://
www.mpdinfo.org), the Mastocytosis Society (http://
www.tmsforacure.org), and several online support
groups (such as http://www.acor.org; http://www.
mpdsupport.org). Among non-US resources are
the Myeloproliferative Disorders Australia (MPD-
Oz; http://www.mpd-oz.org), the Italian Mielofi-
brosi Insieme (for patients with PMF; http://www.
myelofibrosis.net), and the Gruppo Italiano per
le Malattie Ematologiche Maligne dell’Adulto-
GIMEMA (http://www.gimema.org).
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